8-K - MAIA Biotechnology, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

MAIA Biotechnology reported overall survival exceeding two years for eight patients in its ongoing Phase 2 THIO-101 trial of ateganosine sequenced with cemiplimab in NSCLC, presented at ELCC 2026.

Key Takeaways

1Eight patients achieved OS >24 months without subsequent therapy in THIO-101 Parts A/B.

2One 3L patient survived 33 months vs expected 5.8 months.

3Four 2L patients survived >30 months vs standard 10.5 months.

4All eight patients previously failed checkpoint inhibitor therapy alone.

5Part C expansion enrolling up to 48 patients in Asia/Europe.

6Treatment showed acceptable safety in heavily pre-treated NSCLC population.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

** **Other Events.** On March 31, 2026, MAIA Biotechnology, Inc. (the “Company”) issued a press release entitled “MAIA Biotechnology Reports Overall Survival Ex

Other Event

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release dated March 31 2026 | | 104 | | Cover

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1